Metabolomic profile in hyperthyroid patients before and after antithyroid drug treatment: Correlation with thyroid hormone and TSH concentration

2017 ◽  
Vol 93 ◽  
pp. 119-128 ◽  
Author(s):  
Cristina Piras ◽  
Nicolò Arisci ◽  
Simone Poddighe ◽  
Sonia Liggi ◽  
Stefano Mariotti ◽  
...  
Keyword(s):  
Thyroid Hormone ◽  
Drug Treatment ◽  
Antithyroid Drug ◽  
Metabolomic Profile ◽  
Before And After ◽  
Antithyroid Drug Treatment ◽  
Hyperthyroid Patients

scholarly journals The thyroid function of Graves' disease patients is aggravated by depressive personality during antithyroid drug treatment

2011 ◽  
Vol 5 (1) ◽  
pp. 9 ◽  
Author(s):  
Atsushi Fukao ◽  
Junta Takamatsu ◽  
Sumihisa Kubota ◽  
Akira Miyauchi ◽  
Toshiaki Hanafusa
Keyword(s):  
Drug Treatment ◽  
Thyroid Function ◽  
Antithyroid Drug ◽  
Graves Disease ◽  
Antithyroid Drug Treatment ◽  
Depressive Personality

scholarly journals Remission Rate of Graves' Disease and the Trend of Changes in Serum TSH Receptor Antibodies in Prolonged Antithyroid Drug Treatment

2020 ◽  
Vol 18 (Suppl) ◽  
Author(s):  
Danilo Villagelin ◽  
Roberto Bernardo Santos ◽  
João Hamilton Romaldini
Keyword(s):  
Drug Treatment ◽  
Remission Rate ◽  
Antithyroid Drug ◽  
Antithyroid Drugs ◽  
Graves Disease ◽  
Remission Rates ◽  
Thyrotropin Receptor Antibodies ◽  
Antithyroid Drug Treatment ◽  
The Impact ◽  
Receptor Antibodies

Context: Graves’ disease is an autoimmune disease caused by thyrotropin receptor antibodies (TRAb). These antibodies can be measured and used for the diagnosis, prediction of remission, and risk of Graves’ orbitopathy development. There are three treatments for Graves’ disease that have remained unchanged for the last 75 years: Antithyroid drugs, radioiodine, and surgery. Antithyroid drugs are the first treatment option worldwide and are usually used for 12 - 18 months. Recent reports suggest the use of antithyroid drugs for more than 18 months with better outcomes. This review focuses on two aspects of treatment with antithyroid drugs: The impact of using antithyroid drugs for more than 12 - 18 months on remission rates and the trend of TRAb during prolonged antithyroid drug treatment. Evidence Acquisition: A review was performed in Medline on the published work regarding the duration of ATD treatment and remission of Graves' disease and also ATD treatment and TRAb status during the 1990 - 2019 period. Results: Remission rates are variable (30% - 80%), and many clinical and genetic factors serve as predictors. The long-term use of antithyroid drugs appears to increase remission rates. TRAb values usually decline during ATD treatment, but the trend could occur in two ways: Becoming negative or showing a fluctuating pattern. However, approximately 10% of the patients will remain TRAb-positive after five years of treatment with antithyroid drugs. Conclusions: Antithyroid drugs can be used for long periods with an increase in remission rates, and a gradual decrease in TRAb levels, with the disappearance of TRAb in 90% of the patients after 60 months.

scholarly journals MP215CRESCENTIC GLOMERULONEPHRITIS ASSOCIATED WITH ANTITHYROID DRUG TREATMENT

2016 ◽  
Vol 31 (suppl_1) ◽  
pp. i411-i412
Author(s):  
Azza Khedhiri ◽  
Yosr Chaabouni ◽  
Ikram Agrebi ◽  
Aicha Talmoudi ◽  
Houda Feriani ◽  
...  
Keyword(s):  
Drug Treatment ◽  
Antithyroid Drug ◽  
Antithyroid Drug Treatment
Sign in / Sign up

Export Citation Format

Share Document